相关实验视频

Updated: Jun 22, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

在丹麦的临床I阶段精髓瘤患者监测计划中检测复发:一项全国性的研究

Niklas B Lindahl¹, Jakob Lauritsen², Thomas Wagner³

¹Department of Oncology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.

Acta oncologica (Stockholm, Sweden)

|January 31, 2025

概括

临床I期 (CSI) 精髓瘤的积极监测有效地检测复发,主要是通过成像. 复发风险较低的患者可能受益于减少随访,包括减少体检.

科学领域:

在瘤学瘤学.
泌尿器科泌尿器科泌尿器科泌尿器科
癌症监测癌症监测

背景情况:

积极监测是临床第一阶段 (CSI) 精子瘤的标准管理策略.
了解复发检测模式对于优化后续方案至关重要.

研究的目的:

在基于人群的CSI患者队列中确定复发检测方法.
提供证据,以开发一个风险适应的监测计划为seminoma.

主要方法:

来自丹麦丸癌数据库的924名CSI半瘤患者的分析.
对临床数据的回顾性审查,以描述复发检测模式.
探索风险适应方法,将患者分为低风险和非低风险组.

主要成果:

五年累计复发风险为16% (146次复发).
影像检测检测到71%的复发;18%涉及成像和高血清瘤标志物 (STMs).
低风险患者的复发风险为9%,而非低风险患者的复发风险为28%.

结论:

目前的监测有效地检测出早期的半瘤复发.
对于低风险患者,可能会省略例行体检.
需要进一步的研究来完善高风险患者的随访.

更多相关视频

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

相关概念视频

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...